Outlook Therapeutics® to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07 2022 - 8:05AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial
biopharmaceutical company working to develop and launch the first
FDA-approved ophthalmic formulation of bevacizumab for use in
retinal indications, today announced that Russ Trenary, President
and Chief Executive Officer of Outlook Therapeutics, will present
at the H.C. Wainwright 24th Annual Global Investment Conference
being held in New York, NY and virtually on September 12-14, 2022.
In addition to the presentation, management will
be available to participate in virtual one-on-one meetings with
qualified members of the investor community who are registered to
attend the conference. For more information about the conference,
please visit the conference website.
A video webcast of the presentation will be
accessible for viewing on-demand beginning on Monday, September 12
at 7:00 AM ET for those registered for the event and will be
available on the Events page in the Investors section of the
Company’s website (outlooktherapeutics.com). The webcast replay
will be archived for 90 days following the event.
About Outlook Therapeutics,
Inc.
Outlook Therapeutics is a biopharmaceutical
company working to develop and launch ONS-5010/ LYTENAVA™
(bevacizumab-vikg), an investigational therapy, as the first
FDA-approved ophthalmic formulation of bevacizumab for use in
retinal indications, including wet AMD, DME and BRVO. Outlook
Therapeutics has submitted its Biologics License Application
(BLA) to the U.S. Food and Drug Administration (FDA) for
ONS-5010 to treat wet AMD. The submission is supported by Outlook
Therapeutics’ wet AMD registration clinical program, which consists
of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE. If
ONS-5010 ophthalmic bevacizumab is approved, Outlook
Therapeutics expects to commercialize it as the first and only
FDA-approved ophthalmic formulation of bevacizumab for use in
treating retinal diseases in the United States, United
Kingdom, Europe, Japan and other markets. For more
information, please visit www.outlooktherapeutics.com.
CONTACTS:Media
Inquiries:Anna ArmyAccount SupervisorLaVoie Health
ScienceT: 617-351-0246aarmy@lavoiehealthscience.com
Investor
Inquiries: Jenene
ThomasChief Executive OfficerJTC Team, LLCT:
833.475.8247 OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Sep 2023 to Sep 2024